A once-daily, fixed-dose polypill including aspirin, atorvastatin, hydrochlorothiazide and enalapril or valsartan was effective for the prevention of major CV events in adults living in low- and middle-income regions, with high adherence and low adverse events.

According to a new study published in The Lancet, in a cohort of participants living in the low- to middle-income Golestan region of Iran (n = 6,838; aged 40-75 years; 50.4% women; 10.8% preexisting CVD; 15% diabetes), a once-daily polypill in combination with educational training on healthy lifestyle, diet, weight control, and abstinence from smoking and opium, resulted in a lower incidence of major CV events (HR = 0.66; 95% CI, 0.55-0.8) compared with participants who did not receive the polypill. Further, the reduction in risk for major CV events improved with greater adherence to the polypill (HR = 0.43; 95% CI, 0.33-0.55).